Research & Development
Pfizer reports positive Phase 3 results for LITFULO in nonsegmental vitiligo
30 July 2026 - US biopharmaceutical company Pfizer Inc (NYSE:PFE) on Thursday announced positive topline results from two Phase 3 trials evaluating LITFULO (ritlecitinib) as a potential oral systemic ...
European Commission approves RINVOQ for severe alopecia areata
29 July 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) said on Wednesday it has received European Commission approval for RINVOQ (upadacitinib) to treat adults and adolescents aged 12 and ove...
Incyte's Opzelura approved in European Union for moderate atopic dermatitis
29 July 2026 - Biopharmaceutical company Incyte (Nasdaq:INCY) announced on Wednesday that the European Commission has approved Opzelura (ruxolitinib) cream for adults with moderate atopic dermatitis w...
RTW Biotech portfolio company Yarrow Bioscience completes merger
29 July 2026 - Life sciences investment company RTW Biotech Opportunities Ltd (LSE: RTW) announced on Wednesday that portfolio company Yarrow Bioscience has completed its merger with VYNE Therapeutics...
Lupin's Diazepam Injection, USP receives US approval
29 July 2026 - India-based global pharmaceutical company Lupin Limited (BSE:500257) (NSE:LUPIN) announced on Tuesday that it has received approval under the Federal Food, Drug, and Cosmetic Act (FD&am...
Auxilium Health changes name to Aeris Biosciences
29 July 2026 - Biomaterials developer Auxilium Health has announced a rebrand and change of name to Aeris Biosciences.The name Aeris is designed to reflect what the company's biomaterials are at ...